Avalo Therapeutics, Inc.（AVTX）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · AVTX · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2025-12	2024-12	2023-12	2022-12	2021-12
Revenue
Revenue	$0.06M	$0.44M	$1.92M	$18.05M	$5.40M
Cost of Revenue	$0.00M	($0.37M)	$1.28M	$3.43M	$1.49M
Gross Profit	$0.06M	$0.81M	$0.64M	$14.62M	$3.91M
Gross Margin %(computed)	100.00%	182.99%	33.26%	80.98%	72.38%
Operating Expenses
R&D Expenses	$50.08M	$52.08M	$13.78M	$31.31M	$59.84M
G&A Expenses	$22.43M	$16.45M	$10.27M	$20.64M	$23.00M
Total Operating Expenses	$72.98M	$69.32M	$27.99M	$52.06M	$86.04M
Operating Income	($72.92M)	($68.51M)	($27.35M)	($37.44M)	($82.13M)
Operating Margin %(computed)	—	—	—	-207.41%	—
Interest Income	$0.00M	$3.32M	$0.00M	$0.00M	$0.00M
Interest Expense	$0.00M	$0.00M	$3.42M	$4.17M	$2.39M
Income Before Tax	($78.09M)	($35.02M)	($31.53M)	($41.63M)	($84.55M)
Income Tax Expense	$0.17M	$0.11M	$0.01M	$0.03M	($0.20M)
Net Income	($78.26M)	($35.13M)	($31.54M)	($41.66M)	($84.38M)
Net Margin %(computed)	—	—	—	-230.78%	—
Per Share & EBITDA
EPS (Basic)	$-5.84	$-4.32	$-113.58	$-1062.65	$-2330.66
Wtd Avg Shares	13.40M	8.13M	0.28M	0.04M	0.04M
EBITDA	($72.58M)	($68.34M)	($23.29M)	($37.27M)	($80.48M)
EBITDA Margin %(computed)	—	—	—	-206.49%	—